Faculty from the School of Veterinary Medicine and Perelman School of Medicine were honored at the Association for Research in Vision and Ophthalmology meeting in New Orleans.
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
By
Staff
58 seconds ago
NEW YORK–(BUSINESS WIRE)–#EYEN Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.
“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” commented Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term clinical and regulato
E-Mail
Three University of Pennsylvania researchers have been honored by The Sanford and Sue Greenberg Prize to End Blindness by 2020 for their research, which led to the first Food and Drug Administration-approved gene therapy for a genetic disease. Gustavo D. Aguirre of the School of Veterinary Medicine and Jean Bennett and Albert M. Maguire of the Perelman School of Medicine, together with William Hauswirth of the University of Florida, are recipients of the Outstanding Achievement Prize, awarded in a virtual ceremony.
The four scientists share a $1 million prize, funds that will go to support further laboratory and clinical research that advances vision science. Together, their work going from an animal model of disease to human clinical trials led to an FDA-approved gene therapy for Leber congenital amaurosis (LCA) caused by a mutation in the RPE65 gene, a retinal disease that causes visual impairments beginning in infancy. Now commercialized and used routinely, this treatme